Brent Douty, Fallowfield, PA (US); Andrew W. Buesking, Wilmington, DE (US); David M. Burns, Plymouth Meeting, PA (US); Andrew P. Combs, Kennett Square, PA (US); Nikoo Falahatpisheh, Wilmington, DE (US); Ravi Kumar Jalluri, Avondale, PA (US); Daniel Levy, Philadelphia, PA (US); Padmaja Polam, Kennett Square, PA (US); Lixin Shao, Wilmington, DE (US); Stacey Shepard, Wilmington, DE (US); Artem Shvartsbart, Kennett Square, PA (US); Richard B. Sparks, Hockessin, DE (US); and Eddy W. Yue, Landenberg, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Nov. 30, 2021, as Appl. No. 17/537,674.
Application 16/913,488 is a division of application No. 16/163,341, filed on Oct. 17, 2018, granted, now 10,738,057, issued on Aug. 11, 2020.
Application 17/537,674 is a continuation of application No. 16/913,488, filed on Jun. 26, 2020, granted, now 11,225,486.
Claims priority of provisional application 62/727,316, filed on Sep. 5, 2018.
Claims priority of provisional application 62/608,897, filed on Dec. 21, 2017.
Claims priority of provisional application 62/574,057, filed on Oct. 18, 2017.
Prior Publication US 2022/0213107 A1, Jul. 7, 2022
1. A compound which is 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, or a pharmaceutically acceptable salt thereof.